CA
NZ
UK
AU
IND
US
…
Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems. It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -136.64M | -119.15M | -80.52M | -61.32M | -35.80M |
| Net income | -132.10M | -114.67M | -76.50M | -60.33M | -35.80M |
| Selling general administrative | 44.46M | 33.85M | 22.58M | 12.17M | 9.18M |
| Gross profit | - | - | - | - | 0.04M |
| Reconciled depreciation | 5.13M | 4.53M | 3.43M | 1.86M | 0.35M |
| Ebit | -146.31M | -123.63M | -84.55M | -62.30M | -37.29M |
| Ebitda | -141.18M | -119.10M | -81.11M | -60.44M | -36.95M |
| Depreciation and amortization | 5.13M | 4.53M | 3.43M | 1.86M | 0.35M |
| Non operating income net other | 4.54M | -0.05M | 0.59M | - | - |
| Operating income | -141.18M | -119.10M | -81.11M | -62.30M | -37.29M |
| Other operating expenses | 141.18M | 119.10M | 81.11M | 62.30M | 37.33M |
| Interest expense | 4.54M | 0.05M | 0.59M | 0.00M | 0.00M |
| Interest income | 4.54M | - | - | 0.98M | 1.49M |
| Net interest income | 4.54M | -0.05M | 0.59M | 0.98M | 1.49M |
| Income tax expense | -4.54M | -4.48M | -4.02M | -0.98M | 1.49M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.04M |
| Total operating expenses | 141.18M | 119.10M | 81.11M | 62.30M | 37.33M |
| Total other income expense net | 4.54M | -0.05M | 0.59M | 0.98M | 1.49M |
| Net income from continuing ops | -136.64M | -119.15M | -80.52M | -61.32M | -35.80M |
| Net income applicable to common shares | -136.64M | -119.15M | -80.52M | -61.32M | -35.80M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 374.76M | 376.26M | 476.77M | 294.15M | 42.14M |
| Other current assets | 0.29M | 7.53M | 4.04M | 5.41M | 2.63M |
| Total liab | 171.63M | 93.77M | 95.03M | 26.14M | 140.73M |
| Total stockholder equity | 203.13M | 282.49M | 381.75M | 268.01M | -98.59M |
| Deferred long term liab | - | 0.43M | 0.46M | 0.34M | 0.09M |
| Other current liab | 16.53M | 11.40M | 0.68M | 10.95M | 6.91M |
| Common stock | 0.01M | 0.01M | 0.01M | 0.01M | 0.00M |
| Capital stock | 0.01M | 0.01M | 0.01M | 0.01M | 0.00M |
| Retained earnings | -571.38M | -444.76M | -308.13M | -188.97M | -108.45M |
| Other liab | - | - | - | 14.92M | 15.98M |
| Other assets | - | 7.83M | 6.56M | 2.64M | 2.14M |
| Cash | 66.45M | 93.17M | 375.14M | 62.89M | 15.08M |
| Total current liabilities | 39.91M | 19.15M | 18.81M | 11.22M | 9.16M |
| Current deferred revenue | 12.92M | - | 11.50M | - | - |
| Net debt | 31.45M | -11.46M | -294.32M | -62.89M | -15.08M |
| Short term debt | 8.12M | 7.09M | 4.61M | - | - |
| Short long term debt total | 97.89M | 81.71M | 80.83M | - | - |
| Other stockholder equity | 774.22M | 727.34M | 689.87M | 162.82M | 9.86M |
| Property plant equipment | - | 22.21M | 25.89M | 23.78M | 21.84M |
| Total current assets | 272.62M | 287.02M | 379.19M | 267.74M | 18.16M |
| Net tangible assets | - | 282.49M | 381.75M | 268.01M | -98.59M |
| Short term investments | 197.92M | 185.92M | 0.00M | 199.44M | 0.00M |
| Net receivables | 4.15M | 0.40M | 0.40M | 0.25M | 0.45M |
| Inventory | 3.82M | - | - | - | - |
| Accounts payable | 2.35M | 0.66M | 2.02M | 0.27M | 2.25M |
| Accumulated other comprehensive income | 0.27M | -0.08M | - | 0.01M | -2.23M |
| Common stock total equity | - | 0.01M | 0.01M | 0.01M | 0.00M |
| Retained earnings total equity | - | -444.76M | -308.13M | -188.97M | - |
| Non currrent assets other | 0.70M | 7.83M | 6.56M | 2.64M | 2.14M |
| Non current assets total | 102.14M | 89.25M | 97.58M | 26.42M | 23.98M |
| Capital lease obligations | 97.89M | 81.71M | 80.83M | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -192.51M | 198.90M | -199.68M | 67.89M | -69.76M |
| Change to liabilities | -0.59M | 3.59M | -1.44M | 0.76M | 0.22M |
| Total cashflows from investing activities | -192.51M | 193.05M | -205.20M | 47.98M | -69.76M |
| Net borrowings | - | - | -0.04M | - | - |
| Total cash from financing activities | 12.99M | 214.67M | 323.10M | 0.08M | 100.19M |
| Change to operating activities | 2.43M | 2.42M | -0.27M | 14.47M | 4.46M |
| Net income | -136.64M | -119.15M | -80.52M | -61.32M | -35.80M |
| Change in cash | -281.97M | 315.90M | 47.76M | 7.72M | 2.31M |
| Begin period cash flow | 380.84M | 64.94M | 17.18M | 9.47M | 7.16M |
| End period cash flow | 98.86M | 380.84M | 64.94M | 17.18M | 9.47M |
| Total cash from operating activities | -102.45M | -91.82M | -70.14M | -40.35M | -28.12M |
| Issuance of capital stock | 12.36M | 211.88M | 322.75M | 0.00M | 100.19M |
| Depreciation | 5.13M | 4.53M | 3.43M | 1.86M | 0.35M |
| Other cashflows from investing activities | - | 0.10M | - | 67.97M | -66.74M |
| Change to account receivables | - | - | 0.45M | - | - |
| Sale purchase of stock | 13.57M | 214.67M | 323.14M | 0.10M | 100.19M |
| Other cashflows from financing activities | 0.63M | 2.79M | 109.19M | 0.08M | 100.19M |
| Change to netincome | 30.30M | 18.09M | 8.66M | 3.88M | 2.65M |
| Capital expenditures | 8.80M | 5.96M | 5.52M | 19.99M | 3.02M |
| Cash flows other operating | 1.64M | 0.59M | -3.69M | - | - |
| Cash and cash equivalents changes | -281.97M | 315.90M | 47.76M | - | - |
| Change in working capital | 1.05M | 4.17M | -1.71M | 15.23M | 4.68M |
| Stock based compensation | 24.45M | 17.86M | 8.41M | 4.21M | 3.49M |
| Other non cash items | 3.56M | 0.77M | 0.25M | -0.32M | -0.83M |
| Free cash flow | -111.25M | -97.78M | -75.66M | -60.33M | -31.14M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| NVO Novo Nordisk A/S |
-0.68 1.64% |
40.70 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-3.02 0.55% |
547.85 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
- -% |
916.06 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems. It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
| Name | Title | Year Born |
|---|---|---|
| Dr. Cameron Geoffrey McDonough M.D. | Pres, CEO, Sec. & Director | 1970 |
| Dr. Matthew Norkunas M.B.A., M.D. | Chief Financial Officer | 1978 |
| Dr. Matthew Stanton Ph.D. | Chief Scientific Officer | 1973 |
| Dr. Douglas Kerr M.B.A., M.D., Ph.D. | Chief Medical Officer | 1967 |
| Dr. Tracy Zimmermann Ph.D. | Chief Devel. Officer | 1970 |
| Dr. Mark D. Angelino Ph.D. | Co-Founder | 1973 |
| Dr. Robert Kotin Ph.D. | Co-Founder & Advisor | 1956 |
| Ms. Antionette Paone M.B.A., M.S. | Chief Operating Officer | 1978 |
| Dr. Jennifer Elliott Esq., J.D., Ph.D. | Chief Legal Officer | NA |
| Dr. Phillip Samayoa Ph.D. | Chief Strategy Officer | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.26%
Communication Services
-0.18%
Consumer Cyclical
-0.36%
Consumer Defensive
+0.07%
Energy
-0.01%
Financial Services
-0.26%
Financials
-2.20%
Healthcare
-0.55%
Industrials
-0.08%
Real Estate
-0.33%
Technology
-0.70%
Utilities
-0.41%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...